News Releases

Dr. Ways’ Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce’s Goal to Expand Portfolio of Indications for Tildacerfont SAN FRANCISCO --(BUSINESS WIRE)--Jun. 24, 2021-- Spruce Biosciences, Inc.

Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalization in Key Hormone Biomarkers Tildacerfont is First CRF1 Receptor Antagonist Studied Beyond 2 Weeks in CAH SAN FRANCISCO

Richard Auchus , MD, PhD, Presents Phase 2 Data of Tildacerfont in Adult Classic CAH Tildacerfont Demonstrates Normalization of Elevated Hormone Levels Without Increases to Daily Steroid Doses CAHmelia Clinical Program in Adult Classic CAH Underway to Assess Hormone and Steroid Reduction SAN

SAN FRANCISCO --(BUSINESS WIRE)--May 13, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Richard King , Chief

Presentation of Phase 2 Data of Tildacerfont at 23 rd Annual European Congress of Endocrinology   Cash and Cash Equivalents of $148.6 million SAN FRANCISCO --(BUSINESS WIRE)--May 12, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and

Late-Stage CAHmelia Program in Adult Classic CAH Advancing with Majority of Study Sites Active CAHmelia Program Enhanced Following Discussions with FDA - Primary Data Expected in 2022 Amended Debt Facility with SVB Provides Access Up to Additional $25 Million in Non-Dilutive Financing New Drug

Tildacerfont Led to Significant Reductions in Disease Biomarkers Over 12 Weeks Tildacerfont is First CRF1 Antagonist Studied Beyond Two Weeks in CAH CAHmelia Program Underway and Enrolling Patients in U.S. and Europe SAN FRANCISCO --(BUSINESS WIRE)--Mar. 17, 2021-- Spruce Biosciences, Inc.

SAN FRANCISCO --(BUSINESS WIRE)--Mar. 2, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that data from its Phase 1 and 2

SAN FRANCISCO --(BUSINESS WIRE)--Feb. 17, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that the company will participate in

-CAHmelia Adult Classic CAH Program Underway in U.S. and Europe - -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 Polycystic Ovary Syndrome Program Anticipated in Second Half of 2021- -New Patent Issuance Extends Tildacerfont Patent